Illumina United Kingdom

Illumina is a global leader in genomics and human health, innovating the future of precision health. The company develops DNA sequencing and array-based life sciences technologies to enable research discovery and personalized health. Illumina's products and services include sequencing platforms, microarrays, library preparation kits, and software, which are designed to drive research and clinical applications in various fields such as oncology, genetic and infectious diseases, reproductive health, and more. The company's technology empowers innovation toward positive and impactful people- and planet-healing solutions, and its products are used to pioneer advances in these areas. Illumina also offers financial solutions, including leasing and rental options, to make its technology more accessible to customers. Overall, Illumina's core business is focused on providing comprehensive genomic solutions to researchers and clinicians, enabling them to accelerate their discoveries and applications to improve human health.

BlueGnome was founded in in 2002 by a team of scientists who developed a novel mathematical technology for the analysis of genetic data following the sequencing of the human genome in 2000.

With the support of the University of Cambridge and the Wellcome Trust, BlueGnome went on to assemble a world class team of mathematicians, biologists and software engineers with the aim of developing a range of genetic tests which used these advances to improve human health.

In February 2006 BlueGnome released the CytoChip, a powerful new genetic test for the investigation of genetic abnormalities. The CytoChip is now used in over 40 countries world wide. Since 2006 over 100,000 samples have been investigated using the CytoChip, mainly associated with developmental delay or with complex leukaemias. The CytoChip is now used in over 200 labs as a first line cytogenetic test, replacing traditional G-band karyotyping.

In 2008 BlueGnome applied its unique combination of technology and expertise to the problem of counting the chromosomes in a single human cell. In collaboration with some of the world’s leading IVF centres, BlueGnome developed 24sure and in September 2009 the first 24sure baby, Oliver, was born in the UK. 24sure is well positioned to revolutionize the world of IVF, with recent studies showing dramatic improvements to IVF birth rates and corresponding reductions in miscarriage rates. 24sure has the potential to become the defacto standard of care for IVF cycles worldwide and BlueGnome is working to make that vision into a reality.

BlueGnome is privately held, profitable and has been included in the Deloitte Fast 50 for the third year running, recently ranked the 2nd fastest growing biotech company in the UK with over 85% of sales going for export to major laboratories around the world. BlueGnome is now proud to have been awarded the Queen’s Award for Enterprise in International Trade.

The future of BlueGnome is bright, with active research and development into a range of different technologies and software to meet the needs of genetics professionals as the genome revolution continues. BlueGnome is changing the world by producing genetic tests for investigation of intellectual disability, cancer and embryo viability.

Instrument Names : Hi-Seq 2000, Hi-Seq 1000, Genome Analyzer IIx, i-Scan, Hi-Scan , Hi-Scan SQ, Bead Express.
Technology Overview : Illumina are manufacturers of High Throughput Next Generation Sequencing and High Throughput MicroArray Technology.

24sure
CytoChip Cancer
CytoChip ISCA
CytoChip Focus
BlueFish probes
BlueFuse software
ClearLab hardware
Consumables